Simulations Plus (NASDAQ:SLP) Announces Quarterly Earnings Results

Simulations Plus (NASDAQ:SLP) issued its quarterly earnings results on Thursday. The technology company reported $0.31 EPS for the quarter, beating analysts’ consensus estimates of $0.25 by $0.06, Zacks reports. The business had revenue of $22.43 million for the quarter, compared to analysts’ expectations of $21.93 million. Simulations Plus had a net margin of 10.97% and a return on equity of 6.84%. The business’s quarterly revenue was up 22.5% on a year-over-year basis. During the same period last year, the business earned $0.20 earnings per share. Simulations Plus updated its FY25 guidance to $1.07-1.20 EPS and its FY 2025 guidance to 1.070-1.200 EPS.

Simulations Plus Stock Performance

SLP opened at $25.68 on Friday. The company’s 50-day simple moving average is $30.03 and its two-hundred day simple moving average is $30.29. Simulations Plus has a 52-week low of $23.01 and a 52-week high of $51.22. The stock has a market capitalization of $515.96 million, a P/E ratio of 64.20 and a beta of 0.89.

Analysts Set New Price Targets

Several brokerages recently commented on SLP. StockNews.com raised shares of Simulations Plus from a “sell” rating to a “hold” rating in a research note on Friday. KeyCorp boosted their price objective on shares of Simulations Plus from $35.00 to $37.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. Finally, William Blair reiterated an “outperform” rating on shares of Simulations Plus in a report on Wednesday, January 8th. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Simulations Plus presently has an average rating of “Moderate Buy” and a consensus target price of $49.40.

Insider Activity

In related news, Director Walter S. Woltosz sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $33.91, for a total transaction of $678,200.00. Following the completion of the sale, the director now directly owns 3,402,584 shares in the company, valued at approximately $115,381,623.44. The trade was a 0.58 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 19.40% of the stock is owned by corporate insiders.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.